NR3C2 and hydrops fetalis: In HF trials that have published sex-specific results, both sexes respond similarly to standard HF treatments such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, sacubitril/valsartan, beta-blockers, mineralocorticoid receptor antagonists, and sodium glucose transport protein–2 inhibitors (9–13).